Zydus Cadila and TLC from Taiwan make pact to market anti-black fungus drug in India

Zydus Cadila and TLC of Taiwan enter into a pact to commercialize anti-black fungal drugs in India

Zydus Cadila and Taiwan-based pharmaceutical company TLC signed a pact on Wednesday to commercialize liposomal amphotericin B, a key drug used in the treatment of mucormycosis (black mold), in India.

The companies announced that they have signed an agreement to commercialize AmphoTLC (Amphotericin B Liposome For Injection 50 mg) in India, Zydus Cadila said in a statement.

“Given an acute shortage of drugs to treat mucormycosis in India, we are making this critical drug available in India immediately,” said Sharvil Patel, General Manager of Cadila Healthcare. The need of the hour is to combat this life-threatening infection with safe and effective therapy, he added.

The Central Drugs Standard Control Organization has approved DC’s New Drug Use (NDA) for Amphotericin B Liposome For Injection of 50 mg for Immediate Entry as Approved Use and Indication, Zydus Cadila said.

With black fungus cases rising in India in recent days, AmphoTLC will address the acute liposomal amphotericin B deficiency in the country, he added. Mucormycosis is a serious fungal infection, also known as black fungus, and COVID-19-associated mucormycosis is life-threatening, the statement said.

AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis. The shares of Cadila Healthcare, the publicly traded company of the Zydus Group, traded on BSE at 626.45 rupees per share, an increase of 0.64 percent from the previous close. PTI ACT

The Techgadgetguides is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com Inc.
Tech Reviews and Guides | TGG
Compare items
  • Total (0)